Business Monitor International


Austria Pharmaceuticals & Healthcare Report

Published 24 November 2014

  • 74 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Austria Pharmaceuticals & Healthcare Report

BMI View:   The Austrian pharmaceutical and healthcare sectors are well developed and stable, offering some of the most attractive opportunities in the region. While the market will continue to be affected by the drug pricing restrictions and public spending cuts to healthcare being enacted across the region, we hold to our forecasts for steady growth over the duration of our forecast period.

Headline Expenditure Projections

  • Pharmaceuticals: EUR4.58bn (USD6.05bn) in 2013 to EUR4.79bn (USD6.42bn) in 2014; +4.6% in local currency terms and +6.2% in US dollar terms.

  • Healthcare: EUR37.04bn (USD48.89bn) in 2013 to EUR38.36bn (USD51.41bn) in 2014; +3.6% in local currency terms and +5.1% in US dollar terms.   Forecast revised down due to the government's budget concerns and limits on spending.

Risk/Reward Rating

In the latest addition of our Pharmaceutical Risk/Reward Index we have assigned Austria an RRI score for Q115 of 71.6, a slight upwards revision from the previous quarter. Austria continues to rank fifth in the region, scoring above the Western European average of 68.0. Austria holds one of the highest RRI scores globally due to the inherent rewards and low risks that arise from an ageing population, high per capita spending and stable policy environment for drugmakers operating in the country.

Key Trends & Developments

  • In October 2014 it was reported that less than 100 psychiatrists provide publicly funded treatment in Austria, with only 20 psychiatrists in the capital city Vienna according to the Association of Austrian Social Security Institutions. Only one in six people in need of psychotherapy are able to receive publicly funded treatment in Austria, noted Head of the Department of Psychoanalysis and Psychotherapy at Vienna's Medical University Stephan Doering. 'Depression and anxiety disorders alone affect around 1.7mn people in Austria,' said Doering (reports The Local). The country lags behind Germany and Switzerland when it comes to...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2010-2018)
14
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)
17
Prescription Drug Market Forecast
17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
21
Austria
22
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
23
OTC Medicine Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2010-2018)
25
Macroeconomic Forecasts
26
Economic Analysis
26
Table: Austria - Economic Activity
30
Industry Risk Reward Ratings
31
Western Europe Risk/Reward Ratings
31
Austria Risk/Reward Ratings
36
Rewards
36
Risks
37
Market Overview
38
Industry Trends And Developments
40
Epidemiology
40
Regulatory Development
42
Competitive Landscape
47
Pharmaceutical Distribution
49
Pharmaceutical Wholesale
49
Table: Members Of ARGE Pharmazeutika, 2011
50
Pharmaceutical Retail
51
Table: Pharmacy Outlets by Type, 2005-2009
52
Table: Pharmacy Outlets by State, 2005-2009
52
Demographic Forecast
54
Table: Austria's Population By Age Group, 1990-2020 ('000)
55
Table: Austria's population By Age Group, 1990-2020 (% of total)
56
Table: Austria's Key Population Ratios, 1990-2020
57
Table: Austria's Rural And Urban Population, 1990-2020
57
Glossary
58
Methodology
60
Pharmaceutical Expenditure Forecast Model
60
Healthcare Expenditure Forecast Model
60
Notes On Methodology
61
Risk/Reward Ratings Methodology
62
Ratings Overview
63
Table: Pharmaceutical Risk/Reward Ratings Indicators
63
Indicator Weightings
64

The Austria Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Austria Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Austria pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Austria, to test other views - a key input for successful budgeting and strategic business planning in the Austrian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Austrian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Austria.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc